Observational studies of drug safety--aprotinin and the absence of transparency
- PMID: 17124013
- DOI: 10.1056/NEJMp068252
Observational studies of drug safety--aprotinin and the absence of transparency
Comment in
-
Dangerous deception--hiding the evidence of adverse drug effects.N Engl J Med. 2006 Nov 23;355(21):2169-71. doi: 10.1056/NEJMp068246. N Engl J Med. 2006. PMID: 17124012 No abstract available.
-
Research replication.N Engl J Med. 2006 Nov 23;355(21):2252-3. doi: 10.1056/NEJMe068271. N Engl J Med. 2006. PMID: 17124026 No abstract available.
-
Judging the safety of aprotinin.N Engl J Med. 2006 Nov 23;355(21):2262. N Engl J Med. 2006. PMID: 17131514 No abstract available.
Comment on
-
The risk associated with aprotinin in cardiac surgery.N Engl J Med. 2006 Jan 26;354(4):353-65. doi: 10.1056/NEJMoa051379. N Engl J Med. 2006. PMID: 16436767
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources